In VittoComparison Activity ofOPC-17116, a New Fluoroquinolone, Against More Than 5,000 Recent Clinical Isolates from Five Medical Centers
Autor: | Stephen D. Allen, Patrick R. Murray, E. H. Gerlach, Ronald N. Jones, John A. Washington, Helio S. Sader |
---|---|
Rok vydání: | 1993 |
Předmět: |
0301 basic medicine
Bacilli medicine.drug_class 030106 microbiology Antibiotics Microbial Sensitivity Tests Quinolones Piperazines Microbiology 03 medical and health sciences 0302 clinical medicine Anti-Infective Agents medicine Humans Pharmacology (medical) Antibacterial agent Pharmacology Bacteria biology Drug Resistance Microbial biochemical phenomena metabolism and nutrition bacterial infections and mycoses biology.organism_classification Quinolone In vitro Ciprofloxacin Infectious Diseases Oncology 030220 oncology & carcinogenesis Ofloxacin Cefixime Fluoroquinolones medicine.drug |
Zdroj: | Journal of Chemotherapy. 5:283-288 |
ISSN: | 1973-9478 1120-009X |
DOI: | 10.1080/1120009x.1993.11739245 |
Popis: | The in vitro activity of OPC-17116, a new fluoroquinolone, was compared with those of ciprofloxacin, ofloxacin and cefixime. A total of 5,231 fresh clinical isolates from five geographically separate US medical centers were tested. The primary results of this study are: 1. OPC-17116 is very active against Enterobacteriaceae [MIC90s, 0.015-1 microgram/ml, except Providencia rettgeri (MIC90,8 micrograms/ml)], 2. among nonenteric Gram-negative bacilli (e.g. Xanthomonas maltophilia, MIC90, 2 micrograms/ml) and Gram-positive cocci (e.g. oxacillin-susceptible staphylococci, MIC90s, 0.12-0.5 microgram/ml) OPC-17116 demonstrated higher activity than ciprofloxacin or ofloxacin, 3. the quinolones were more active than cefixime against most of the species tested, especially against Gram-positive and non-enteric Gram-negative organisms. The results of this study, associated with prior documented favorable qualities, support continued investigation of OPC-17116 for clinical use. |
Databáze: | OpenAIRE |
Externí odkaz: |